S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NYSE:BDX

Becton, Dickinson and - BDX Competitors

$240.25
+1.76 (+0.74%)
(As of 03/21/2023 04:22 PM ET)
Add
Compare
Today's Range
$237.85
$240.78
50-Day Range
$229.71
$256.15
52-Week Range
$215.90
$277.29
Volume
1.10 million shs
Average Volume
1.14 million shs
Market Capitalization
$68.21 billion
P/E Ratio
45.33
Dividend Yield
1.52%
Price Target
$271.89

BDX vs. BSX, DXCM, RMD, SYK, PODD, BAX, WST, HCA, GSK, and HUM

Should you be buying Becton, Dickinson and stock or one of its competitors? The main competitors of Becton, Dickinson and include Boston Scientific (BSX), DexCom (DXCM), ResMed (RMD), Stryker (SYK), Insulet (PODD), Baxter International (BAX), West Pharmaceutical Services (WST), HCA Healthcare (HCA), GSK (GSK), and Humana (HUM). These companies are all part of the "medical" sector.

Becton, Dickinson and vs.

Becton, Dickinson and (NYSE:BDX) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.

Becton, Dickinson and has a net margin of 8.47% compared to Boston Scientific's net margin of 5.50%. Boston Scientific's return on equity of 14.29% beat Becton, Dickinson and's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and 8.47% 13.52% 6.36%
Boston Scientific 5.50% 14.29% 7.67%

In the previous week, Boston Scientific had 19 more articles in the media than Becton, Dickinson and. MarketBeat recorded 31 mentions for Boston Scientific and 12 mentions for Becton, Dickinson and. Becton, Dickinson and's average media sentiment score of 0.81 beat Boston Scientific's score of 0.21 indicating that Becton, Dickinson and is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
5 Very Positive mention(s)
3 Positive mention(s)
17 Neutral mention(s)
4 Negative mention(s)
2 Very Negative mention(s)
Neutral

Becton, Dickinson and presently has a consensus target price of $271.89, suggesting a potential upside of 13.35%. Boston Scientific has a consensus target price of $51.50, suggesting a potential upside of 5.77%. Given Becton, Dickinson and's higher probable upside, research analysts plainly believe Becton, Dickinson and is more favorable than Boston Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Boston Scientific
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
3.00

Becton, Dickinson and has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Boston Scientific received 368 more outperform votes than Becton, Dickinson and when rated by MarketBeat users. Likewise, 69.96% of users gave Boston Scientific an outperform vote while only 62.42% of users gave Becton, Dickinson and an outperform vote.

CompanyUnderperformOutperform
Becton, Dickinson andOutperform Votes
573
62.42%
Underperform Votes
345
37.58%
Boston ScientificOutperform Votes
941
69.96%
Underperform Votes
404
30.04%

Becton, Dickinson and has higher revenue and earnings than Boston Scientific. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$18.87 billion3.61$1.78 billion$5.3045.26
Boston Scientific$12.68 billion5.51$698 million$0.45108.20

87.1% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 90.2% of Boston Scientific shares are owned by institutional investors. 0.3% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Boston Scientific beats Becton, Dickinson and on 13 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDX vs. The Competition

MetricBecton, Dickinson andSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$68.10B$3.35B$4.29B$14.24B
Dividend Yield1.55%3.13%5.99%3.94%
P/E Ratio45.2656.6399.6819.44
Price / Sales3.6128.963,489.0210.30
Price / Cash12.0436.1519.8116.34
Price / Book2.714.314.536.98
Net Income$1.78B$57.78M$114.48M$874.19M
7 Day Performance2.99%-0.44%-1.72%-0.89%
1 Month Performance0.15%-0.92%-5.81%-6.36%
1 Year Performance-10.37%-24.52%-14.36%-13.66%

Becton, Dickinson and Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BSX
Boston Scientific
2.5741 of 5 stars
$47.97
-0.7%
$51.50
+7.4%
+10.4%$68.83B$12.68B106.6045,000News Coverage
DXCM
DexCom
2.2401 of 5 stars
$113.72
+0.5%
$123.00
+8.2%
+0.2%$43.94B$2.91B139.967,600
RMD
ResMed
2.9134 of 5 stars
$207.99
-0.3%
$263.17
+26.5%
-19.4%$30.56B$3.58B37.758,160
SYK
Stryker
2.709 of 5 stars
$273.03
-1.0%
$272.00
-0.4%
+3.5%$103.43B$18.45B44.2551,000
PODD
Insulet
2.0374 of 5 stars
$307.89
-1.6%
$317.82
+3.2%
+22.4%$21.41B$1.31B5,131.502,600
BAX
Baxter International
2.9874 of 5 stars
$38.23
-2.9%
$55.14
+44.2%
-51.7%$19.29B$15.11B-7.9260,000
WST
West Pharmaceutical Services
2.5371 of 5 stars
$325.59
-0.9%
$291.25
-10.5%
-19.9%$24.14B$2.89B42.1713,550
HCA
HCA Healthcare
2.6485 of 5 stars
$247.47
-1.3%
$269.41
+8.9%
-1.6%$68.54B$60.23B12.87294,000
GSK
GSK
2.3144 of 5 stars
$33.58
-0.4%
N/A-18.8%$68.74B$36.28B3.9190,096
HUM
Humana
3.1358 of 5 stars
$483.87
+0.4%
$594.12
+22.8%
+12.2%$60.47B$92.87B21.9567,100
This page (NYSE:BDX) was last updated on 3/21/2023 by MarketBeat.com Staff